All In Biotech

Drug Trial Radar · NCT00105144

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia

Last checked: Nov 19, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

611

Actual

Start

Sep 2004

Primary completion

Apr 2006

Study completion Apr 2006

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Mar 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.

Conditions

  • Candidiasis
  • Candidemia

Interventions

  • MicafunginDrug

    IV

  • CaspofunginDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall treatment success, based on the investigator's assessment of pre-defined clinical and mycological response at the End of intravenous (IV) TherapyTime frame: End of therapy and 6 weeks post-treatment

Locations

167 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Denver, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Bay Pines, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Beech Grove, Indiana

  • Site not named

    Evansville, Indiana

  • Site not named

    Des Moines, Iowa

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Neptune City, New Jersey

  • Site not named

    Albany, New York

  • Site not named

    Manhasset, New York

  • Site not named

    New Hyde Park, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.